Response

Affiliations

• ¹ Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO).
• ² Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA (PL, JAM, CSF, SO); Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK (PL); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (CSF); Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SO); Department of Epidemiology, Harvard School of Public Health, Boston, MA (SO). shuji_ogino@dfci.harvard.edu.